Related Experiment Video

Updated: Mar 20, 2026

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.5K

Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation

Wei Ming1, Gan Lu2, Sha Xin3

  • 1State Key Laboratory of Cancer Biology, Department of Pharmacogenomics, Fourth Military Medical University, Xi'an 710032, PR China; Department of Pharmacology, Xi'an Medical University, Xi'an 710021, PR China.

Biochemical and Biophysical Research Communications
|May 31, 2016
PubMed

Insights

Mitochondria-related peptide MOTS-c protects against osteoporosis by inhibiting osteoclast differentiation. This peptide therapy shows promise for treating bone loss by targeting the AMPK pathway.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Endocrinology

Background:

  • Osteoporosis is characterized by significant bone loss.
  • Therapeutic strategies primarily focus on targeting bone loss.
  • Mitosomes-related peptide MOTS-c is a novel peptide with potential therapeutic applications.

Purpose of the Study:

  • To investigate the efficacy of MOTS-c in preventing ovariectomy-induced osteoporosis in mice.
  • To elucidate the underlying molecular mechanisms of MOTS-c action in bone metabolism.

Main Methods:

  • Ovariectomy-induced osteoporosis model in mice.
  • Administration of MOTS-c (5 mg/kg daily for 12 weeks).
  • Micro-computed tomography (micro-CT) for bone analysis.
  • Assessment of osteoclast differentiation and receptor activator of nuclear factor-κB ligand (RANKL) induction.
  • Measurement of phosphorylated AMP-activated protein kinase (AMPK) levels.
  • Inhibition of AMPK using compound C.

Main Results:

  • MOTS-c treatment significantly alleviated bone loss in mice.
  • MOTS-c markedly inhibited RANKL-induced osteoclast differentiation.
  • MOTS-c increased phosphorylated AMPK levels.
  • AMPK inhibition partially reversed MOTS-c's effects on osteoclastogenesis.

Conclusions:

  • MOTS-c demonstrates a protective effect against osteoporosis.
  • MOTS-c inhibits osteoclast differentiation through an AMPK-dependent pathway.
  • MOTS-c represents a potential therapeutic agent for osteoporosis treatment.
Keywords:
AMPKMOTS-cOsteoblastOsteoclastOsteoporosis

More Related Videos

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

1.5K
Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice07:20

Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice

Published on: August 23, 2024

1.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.6K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
4.2K